格隆汇9月3日丨TATA健康(01255.HK)公告，王俭因其决定将更多时间投入其他工作安排，已提呈辞任 独立非执行董事，并不再担任公司审核委员会、薪酬委员会及提名委员会各自主席，自2025年9月3日起 生效。独立非执行董事黄琳替任王获委任为审核委员会、薪酬委员会及提名委员会主席，自2025年9月3 日起生效。 ...

独立非执行董事黄琳女士已替任王俭先生获委任为审核委员会、薪酬委员会及提名委员会主席。 林哲明先生因其决定将更多时间投入其他工作安排，已提呈辞任非执行董事。 赖文敬先生因其决定将更多时间投入其他工作安排，已提呈辞任公司首席财务官。 智通财经APP讯，TATA健康(01255)发布公告，自2025年9月3日起生效：王俭先生因其决定将更多时间 投入其他工作安排，已提呈辞任独立非执行董事，并不再担任公司审核委员会、薪酬委员会及提名委员 会各自的主席。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：1255） 董事會會議召開日期 及 繼續暫停買賣 茲提述TATA健康國際控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」） 之董事（「董事」）會（「董事會」）日期為二零二四年三月十八日、二零二四年三月二十 五日、二零二四年四月十八日、二零二四年六月五日、二零二四年七月三十一日及 二零二四年九月三十日的公告（統稱「該等公告」），內容有關批准（其中包括）本集團 截至二零二三年十二月三十一日止年度的綜合年度業績（「二零二三年年度業績」）的 董事會會議日期（及其推遲日期）。除另有界定者外，本公告所用詞彙與該等公告所 界定者具有相同涵義。 繼續暫停買賣 應本公司要求，本公司股份已於二零二四年四月二日上午九時正起於聯交所暫停買 賣，並將繼續暫停買賣直至符合復牌指引為止。本公司將適時另行刊發公告，讓公 眾知悉最新發展。 – 1 – 本公司股東及潛在投資者務請審慎投資並注意投資風險。 TATA He ...

（於開曼群島註冊成立的有限公司） （股份代號：1255） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 進一步延遲刊發二零二三年年度業績、二零二四年中期業績及 二零二四年年度業績及 進一步延遲寄發二零二三年年報、二零二四年中期報告及 二零二四年年報 及 延遲刊發二零二五年中期業績及 延遲寄發二零二五年中期報告 及 繼續暫停買賣 茲提述TATA健康國際控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）之 董事（「董事」）會（「董事會」）根據（其中包括）聯交所證券上市規則（「上市規則」）第 13.09(2)(a)、13.24A、13.46(2)及13.49(1)條以及香港法例第571章證券及期貨條例 （「證券及期貨條例」）第XIVA部項下的內幕消息條文（定義見上市規則）於二零二四 年三月二十五日、二零二四年四月二 ...

TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） 董事名單與其角色和職能 TATA健康國際控股有限公司董事會（「董事會」）成員載列如下： 非執行董事 朱俊豪先生 張鳴琪先生 陳琦先生 獨立非執行董事 香港，二零二五年九月三日 黃琳女士 李亮先生 杜建峰先生 董事會設立3個委員會。各董事會成員在這些委員會中所擔任的職位載列如下： 審核委員會 黃琳女士（主席） 李亮先生 杜建峰先生 薪酬委員會 黃琳女士（主席） 李亮先生 杜建峰先生 提名委員會 黃琳女士（主席） 李亮先生 杜建峰先生 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） (1)獨立非執行董事辭任及董事委員會組成之變更； (2)非執行董事辭任； (3)首席財務官辭任；及 (4)不符合上市規則第3.10(2)條 (1) 獨立非執行董事辭任及董事委員會組成之變更 TATA健康國際控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣 佈，王儉先生（「王先生」）因其決定將更多時間投入其他工作安排，已提呈辭任 獨立非執行董事，並不再擔任本公司審核委員會（「審核委員會」）、薪酬委員會 （「薪酬委員會」）及提名委員會（「提名委員會」）各自之主席，自二零二五年九月 三日起生效。 王先生已確認，彼與董事會並無意見分歧，亦無有關彼辭任的其他事宜須提請 本公司股東及香港聯合交易所有限公司（「 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: TATA健康國際控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | | 5,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | | 5, ...

另一方面，鉴于商赢自上次于2021年5月24日存档(即使于订立转让契据后)以来并无存档任何其后的披 露权益通知，这显示商赢仍为拥有上述149,993,617 股股份(包括抵押股份)表决权的实益拥有人。因此， 根据收购守则规则26.1，本公司30%或以上表决权的控制权应该不会发生变更，因此不会因订立转让契 据而触发全面要约责任。 要约期自2020年5月12日起时间跨度已超过五年。根据上述情况，本公司认为抵押股份的要约不太可能 即将发生。因此，经参考应用指引24，要约期已于2025年6月2日结束。 于要约期结束后，本公司不再根据收购守则规则3.7的规定进一步刊发每月公告。 此外，公司股份继续停牌。 此外，接管人已知会本公司，彼等已不再为抵押股份的共同及个别接管人及管理人，自2025年6月2日起 生效。 与此同时，据本公司所知，特别是根据众和国际控股有限公司(众和)于2025年6月2日存档的披露权益通 知(披露权益通知)(经众和于2025年7月17日存档的另一份披露权益通知所修订及取代)，本公司注意到于 2025年5月30日，众和与Great Wall International Investment X Limi ...

Group 1 - The chip sector is experiencing significant stock price increases, with notable gains from companies such as Sitaiwei (up 6.01%), Chipone (up 5.42%), and Anji Technology (up 4.66%) as of June 30, 2025 [1] - The Tianhong CSI Chip Industry ETF closely tracks the CSI Chip Industry Index, which includes 50 leading companies across the entire chip supply chain, reflecting the overall performance of China's listed semiconductor companies [1] - As of June 27, the top ten constituents of the CSI Chip Industry Index include SMIC, North Huachuang, Haiguang Information, and Cambrian, with a combined weight of 54.62% [1][2] Group 2 - Cambrian announced an adjustment to its share repurchase price ceiling from RMB 297.77 per share to RMB 818.87 per share, with its stock price at RMB 585.50 per share as of June 27 [4] - The SEMI report indicates that global front-end semiconductor suppliers are accelerating expansion to meet the rising demand for generative AI applications, with a projected compound annual growth rate of 7% from 2024 to 2028, reaching a record monthly capacity of 11.1 million wafers [4] - Domestic demand for photolithography machines remains strong, as they are the largest segment in semiconductor equipment, with expectations for continued expansion of domestic wafer fabs [4] Group 3 - The domestic large model sector is entering an accelerated release cycle, with companies like MiniMax launching several new models and OpenAI's CEO hinting at the upcoming release of GPT-5, indicating growing competition and investment opportunities in the AI application industry [5]

Revenue Performance - The footwear business generated revenue of approximately HKD 100.7 million, a 62.5% increase compared to approximately HKD 62 million in the same period last year, accounting for about 97% of total revenue[6]. - For the six months ended June 30, 2023, total revenue was HKD 104,131,000, with external sales from footwear products contributing HKD 100,660,000 and online medical services contributing HKD 102,000[67]. - The group achieved a profit of approximately HKD 3,400,000 in the first half of 2023, a 240% increase compared to the same period last year, primarily driven by consulting revenue of about HKD 1,700,000 and investment management revenue of approximately HKD 900,000[136]. - The financial services segment reported revenue of approximately HKD 3,400,000, a significant increase from HKD 1,000,000 in the same period of 2022, attributed to improved economic conditions and increased demand for consulting and investment management services[145]. - The revenue from the mainland China market was HKD 104,131,000, significantly higher than the HKD 63,516,000 reported in the previous year, indicating a strong market performance[197]. - The total revenue from the Macau market was HKD 8,968,000, compared to HKD 4,859,000 in the same period last year, showing an increase of 84.5%[197]. Sales and Growth - Same-store sales rose by approximately 54.3%, compared to a decline of 2.6% in the same period last year[6]. - The footwear business sales increased by 65.5% in the first half of 2023, with expectations for continued growth in the second half[11]. - Sales of footwear products reached HKD 100,660,000, significantly up from HKD 61,951,000 in the previous year[189]. - Retail sales accounted for HKD 98,466,000, an increase from HKD 60,208,000 in the prior year[189]. - The group plans to focus on developing financing consulting services and exploring new market opportunities, such as Singapore, in the second half of 2023[140]. Financial Performance - Gross profit for the period was approximately HKD 85.2 million, a 62.2% increase from approximately HKD 52.5 million in the same period last year, with a gross margin of approximately 81.9%[22]. - The company reported a total segment loss of HKD 6,048,000, with the footwear segment loss at HKD 1,254,000 and online medical services loss at HKD 4,457,000[67]. - The company incurred a pre-tax loss of HKD 14,290,000 for the six months ended June 30, 2023, compared to a profit of HKD 20,169,000 for the same period in 2022[78]. - The company reported a loss before tax of HKD 14,290,000 for the six months ended June 30, 2023, compared to a profit of HKD 16,706,000 in the same period last year[175]. - The company reported a loss attributable to shareholders of HKD 12,327,000 for the first half of 2023, compared to a profit of HKD 20,169,000 in the prior year, indicating a significant decline in profitability[129]. Cost and Expenses - Employee costs for the period were approximately HKD 39.1 million, accounting for about 37.6% of revenue, down from 60.1% in the same period last year[23]. - Administrative expenses increased by approximately HKD 22,000,000 compared to the same period in 2022, primarily due to rising medical expenses and director salaries in the footwear business[134]. - The group’s sales cost for the reporting period was approximately HKD 19,000,000, accounting for about 18.1% of revenue, compared to HKD 11,000,000 and 17.3% in the same period of 2022[148]. Assets and Liabilities - As of June 30, 2023, the group's debt-to-equity ratio was approximately 356.3%, a significant increase from 102.6% on December 31, 2022, primarily due to increased current liabilities of approximately HKD 20 million[28]. - The group's current liabilities exceeded current assets by approximately HKD 63,999,000 as of June 30, 2023, compared to HKD 48,415,000 as of December 31, 2022[58]. - The total assets as of June 30, 2023, amounted to HKD 187,227,000, an increase from HKD 176,052,000 as of December 31, 2022[70]. - The total liabilities increased to HKD 180,569,000 from HKD 157,115,000, with segment liabilities for footwear at HKD 87,110,000 and online medical services at HKD 27,177,000[70]. - The net asset value decreased to HKD 6,658,000 as of June 30, 2023, from HKD 18,937,000 as of December 31, 2022[178]. Operational Insights - The total number of registered users for the internet hospital reached 114,297, with approximately 17,080 online consultation orders received[9]. - The healthcare business reported zero revenue during the period, down from HKD 200,000 in the same period last year, due to operational suspension[134]. - The group has identified potential business development opportunities and acquisition targets in the healthcare sector, with a focus on high-growth investment goals[35]. - The group decided to pause the development of its Australian healthcare business due to market instability and funding concerns, while seeking financing to continue promoting high-margin natural health products[12]. Management and Governance - The group has not declared an interim dividend for the reporting period, consistent with the previous year[38]. - The company is actively seeking suitable candidates to fill vacancies in the board and committees to comply with listing rules[173]. - The company has not held its annual general meeting within the required timeframe, constituting a breach of listing rules[171]. - The board is committed to ensuring financial resources are utilized in a cost-effective manner to fulfill the group's financial responsibilities[29].